Загрузка...
Pharmacogenomics in Early Phase Oncology Clinical Trials: Is There a Sweet Spot in Phase II?
Many clinical trials of oncology drugs now include at least a consideration of pharmacogenomics, the study of germline or acquired genetic factors governing a drug's response and toxicity. Besides the potential benefit to patients from the consideration of personalized pharmacogenomic informati...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2012
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3354016/ https://ncbi.nlm.nih.gov/pubmed/22427349 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-2445 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|